A subpopulation of tissue remodeling monocytes stimulates revascularization of the ischemic limb
Ashish S. Patel,Francesca E. Ludwinski,Alexander Kerr,Simon Farkas,Puja Kapoor,Laura Bertolaccini,Ramon Fernandes,Paul R. Jones,Donal McLornan,Lefteris Livieratos,Prakash Saha,Alberto Smith,Bijan Modarai
DOI: https://doi.org/10.1126/scitranslmed.adf0555
IF: 17.1
2024-06-20
Science Translational Medicine
Abstract:Despite decades of effort aimed at developing clinically effective cell therapies, including mixed population mononuclear cells, to revascularize the ischemic limb, there remains a paucity of patient-based studies that inform the function and fate of candidate cell types. In this study, we showed that circulating proangiogenic/arteriogenic monocytes (PAMs) expressing the FcγIIIA receptor CD16 were elevated in patients with chronic limb-threatening ischemia (CLTI), and these amounts decreased after revascularization. Unlike CD16-negative monocytes, PAMs showed large vessel remodeling properties in vitro when cultured with endothelial cells and smooth muscle cells and promoted salvage of the ischemic limb in vivo in a mouse model of hindlimb ischemia. PAMs showed a propensity to migrate toward and bind to ischemic muscle and to secrete angiogenic/arteriogenic factors, vascular endothelial growth factor A (VEGF-A) and heparin-binding epidermal growth factor. We instigated a first-in-human single-arm cohort study in which autologous PAMs were injected into the ischemic limbs of five patients with CLTI. Greater than 25% of injected cells were retained in the leg for at least 72 hours, of which greater than 80% were viable, with evidence of enhanced large vessel remodeling in the injected muscle area. In summary, we identified up-regulation of a circulatory PAM subpopulation as an endogenous response to limb ischemia in CLTI and tested a potentially clinically relevant therapeutic strategy.
cell biology,medicine, research & experimental